Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Chemotherapy
  •  Molecular Biology
  •  Cardiac Surgery
  •  Gastric Cancer
  •  Microbiology
  •  Nursing
  •  Diabetology
  •  Respiratory Medicine


Citation: Ann Clin Case Rep. 2022;7(1):2077.DOI: 10.25107/2474-1655.2077

No Increase of Toxicity in a Patient with Cutaneous Mastocytosis Treated with Radiotherapy for Breast Cancer: A Case Report

Anna G Balt1*, Marco van Coevorden2 and Paul M Jeene1

1Radiotherapiegroep, Location Deventer, The Netherlands
2Gelre Hospitals, Location Apeldoorn, The Netherlands

*Correspondance to: Anna G Balt 

 PDF  Full Text Case Report | Open Access


Cutaneous mastocytosis is characterized by an increase in mast cells in the cutaneous tissues. There are four main forms, among them urticaria pigmentosa, which presents as red, yellow or brown macules, papules and patches. Radiotherapy is known to cause skin toxicity, hence synergistic toxicity could potentially occur. To the best of our knowledge, no literature exists on the possible interaction between cutaneous mastocytosis and radiotherapy. Here we report a 59-year-old female with cutaneous mastocytosis of the urticaria pigmentosa subtype. Clinical symptoms of cutaneous mastocytosis were reddish brown macules with occasional itching. Current treatment consisted of levocetirizine 5 mg, 1-2 tablets a day and famotidine 20 mg, 1-2 tablets a day. When complaints increased, she used talcum powder and topical chlorhexidine solution for an intertriginous component with generally good results. She was diagnosed with a cT1bN0M0 invasive lobular carcinoma of the right breast. After a breast conserving resection, she was treated with adjuvant radiotherapy in 15 fractions of 2.67 Gy to the whole right breast. Prior to radiotherapy moderate skin lesions of the breast were present without complaints. During radiotherapy, complaints of itching, redness and papillae increased. Furthermore, she experience stabbing pains in her breast and a sore nipple, which was considered as radiation toxicity CTCAE grade 1. No excess acute radiation toxicity was observed. Three months after the radiotherapy the complaints that occurred during radiotherapy had almost completely subsided. Skin lesions were comparable prior to treatment. Two years after radiotherapy the patient reported a decrease in papules and itching of the skin of the right breast. We described a patient with cutaneous mastocytosis treated with adjuvant radiotherapy of the breast. No excess acute or late toxicity was observed.


Cutaneous mastocytosis; Radiotherapy; Breast cancer; Toxicity

Cite the Article:

Balt AG, van Coevorden M, Jeene PM. No Increase of Toxicity in a Patient with Cutaneous Mastocytosis Treated with Radiotherapy for Breast Cancer: A Case Report. Ann Clin Case Rep. 2022; 7: 2077.

Search Our Journal

Journal Indexed In

Articles in PubMed

A New Minimally Invasive Procedure for Muscle, Back, Neck Pain and Radiculopathy - The Myofascial Nerve Block
 PubMed  PMC  PDF  Full Text
Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Clinical Course and Virus Shedding of Mild and Moderate COVID-19 in South China: A Retrospective Study
 Abstract  PDF  Full Text
Expending the Mutational Spectrum of Xia-Gibbs and Bosch-Boonstra-Schaaf Optic Atrophy Syndromes
 Abstract  PDF  Full Text
View More...